

DAFTAR PUSTAKA

- Agrawal, S., Zaritsky, J., Fornoni, A. and Smoyer, W. 2018. Dyslipidemia in Nephrotic Syndrome: Mechanisms and Treatment. **Nature Reviews Nephrology**, vol 14, pp. 57-70.
- Alatas, H., Trihono, PP. PP., Tambunan, T & Pardede, S. O. 2012. **Konsensus Tata Laksana Sindrom Nefrotik Idiopatik pada Anak**. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia, pp. 1-36.
- Anandkumar, S et al. 2016. Clinical Efficacy Study of Atorvastatin, Simvastatin and Pravastatin in Hyperlipidemic Patients. **International Journal of Pharmacy & Pharmaceutical Research**, vol. 6 (4), pp. 523-530.
- Andrade, Junior, M. 2018. Lipoprotein Lipase: A General Review. **Insights in Enzyme Research**, vol.2 No.1:3, pp. 1-14.
- Arshad, A. 2014. Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: An Open-Label Randomized Trial. **Journal of Lipids**, pp. 1-5.
- Astuti, K. D., Muryawan, M. H., Mellyana, O. 2015. Correlation Between Lipid Profile and C-reactive protein in Children with Nephrotic Syndrome. **Paediatrica Indonesiana**, vol. 55, No. 1, pp. 1-6.
- Avis HJ, Vissers MN, Stein EA, et al. Asystematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. **Arterioscler Thromb Vasc Biol**. 2007;27(8):1803–1810
- Avis, H. J., Vissers, M. N., Stein, E. A, et al. 2007. A Systematic Review and Meta Analysis of Statin Therapy in Children with Familial Hypercholesterolemia. **Arteriosclerosis, Thrombosis, and Vascular Biology**, vol. 27, no. 8, pp. 1803–1810.
- B., S., B., M., & Joseph, N. 2019. Comparative Study of Lipid Profile Abnormalities in First Episode and Relapse Cases of Childhood Nephrotic Syndrome. **International Journal of Contemporary Pediatrics**, vol 3, pp. 1297-1300.
- Balakumar, P., & Mahadevan, N. 2012. Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?. **British journal of pharmacology**, 165 (2), pp. 373–379.
- Baxter, J. H., Goodman, H. C., Allen, J. C. 1987. Effects of Infusions of Serum Albumin on Serum Lipids and Lipoprotein in Nephrosis. **The Journal of Clinical Investigation**, vol. 40 (3), pp. 490-498.
- Bayly, G. 2014. Lipids and Disorders of Lipoprotein Metabolism. *Clinical Biochemistry : Metabolic and Clinical Aspects*, ppp.702-736.
- Belay, B., Belamarich, PP., & Tom-Revzon, C. 2007. The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions. **Pediatrics**, vol. 119 (2), pp. 370-380.

- Bobkova, I., Chebotareva, N., Kozlovskaya, L. and Shilov, E. 2016. Edema in Renal Diseases – Current View on Pathogenesis. **Nephrology Point of Care**, vol. 2 (1), pp. 1-9.
- Boullart, A. C. I., J. de Graff, Stalenhoef, A. F. 2012. Serum Trygliceride and Risk of Cardiovascular Disease. **Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids**, vol. 1821 (5), pp. 867-875.
- Bushara, H. M., Ahmed, E. M. 2006. Hyperlipidemia in Children with Nephrotic Syndrome in Khartoum State. Faculty of Medicine. Islamic University.
- Chan, M. K., Persaud, J.W., Varghese, Z., Moorhead, J. 1984. Post heparin hepatic and lipoprotein lipase activator in nephrotic syndrome. **Australian and New Zealand Journal of Medicine**, vol. 14 (6), pp. 841-847.
- Clee SM, Bissada N, Miao F, Miao L, Marais AD, Henderson HE, Steures P et al. 2000. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. **J Lipid Res**, 41(4), pp.521-531
- Cohen, E. PP., Lippold, C. 2019. Nephrotic Syndrome. Accessed in 08/24/2019 <https://emedicine.medscape.com/article/244631>.
- David Alpers. 2008. Role of Lipoprotein Lipase in triglyceride metabolism: potential therapeutic target. **Future Lipidology**, vol 4, pp. 385-397.
- Davidson, M. H. 2011. A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. **Journal of Clinical Lipidology**, vol 5 (2), pp. 76–81.
- Ding, W. and Saleem, M. 2012. Current Concepts of the Podocyte in Nephrotic Syndrome. **Kidney Research and Clinical Practice**, vol 2, pp.87-93.
- Downie, M., Gallibois, C., Parekh, R. and Noone, D. 2017. Nephrotic Syndrome in Infants and Children: Pathophysiology and Management. **Paediatrics and International Child Health**, vol 37, pp. 248-258.
- Dragana N, Andreea Corina, Peter. P. Toth, Lubna Hammad & Manfredi Rizzo. 2019. Choosing an ideal pharmacotherapeutic strategy for dyslipidemia in children. **Expert Opinion on Pharmacotherapy**, 20(3), pp.241-244. <https://doi.org/10.1080/14656566.2018.1552942>
- Eiland, L. S., Luttrell, PP. K. 2010. Use of Statins for Dyslipidemia in the Pediatric Population. **The Journal of Pediatric Pharmacology and Therapeutics**, vol 15 (3), pp. 160–172.
- Endo, K., Miyashita, Y., Saiki, A., Oyama, T. 2004. Atorvastatin and Pravastatin Elevated Pre-heparin Lipoprotein Lipase Mass of Type 2 Diabetes with Hypercholesterolemia. **Journal of Atherosclerosis and Thrombosis**, vol 11, pp. 341–347.
- Feingold KR, Grunfeld C. Cholesterol Lowering Drugs. 2018. Endotext [Internet]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK395573/>

- Filippas-Ntekouan S, Elisaf M S. 2016. Pathophysiological Mechanisms of Dyslipidemia in Patients with Nephrotic Syndrome: A Fresh Look. **Hellenic Journal Atherosclerosis**, vol 7 (3), pp. 102-110.
- Floege, J. and Feehally, J. 2010. Introduction to Glomerular Disease. **Comprehensive Clinical Nephrology**, pp.193-207.
- Florentin M., Liberopoulos E., Elisaf M. 2008. Ezetimibe-associated adverse effects: what the clinician needs to know. **International Journal of Clinical Practice**, vol. 62 (1), pp. 88–96.
- Garcia-Rios A, Nikolic D, Perez-Martinez P, et al. 2014. LDL and HDL Subfractions, Dysfunctional HDL: treatment options. **Current Pharmaceutical Design**, vol 20 (40), pp. 6249–6255.
- Girona, J., Rodríguez-Borjabad, C., Ibarretxe, D., Heras, M., Amigo, N., Feliu, A., et al. 2018. Plasma inducible degrader of the LDLR, soluble low-density lipoprotein receptor, and proprotein convertase subtilisin/kexin type 9 levels as potential biomarkers of familial hypercholesterolemia in children. **Journal of Clinical Lipidology**, vol 12, ppp.211-218.
- Gupta, S., Pepper, R., Ashman, N. and Walsh, S. 2019. Nephrotic Syndrome: Oedema Formation and Its Treatment with Diuretics. **Frontiers in Physiology**, vol 9, pp. 1-10.
- Hari, PP., Khandelwal, PP., Satpathy, A., Hari, S., Thergaonkar, R., Lakshmy, R., Sinha, A. and Bagga, A. 2018. Effect Of Atorvastatin On Dyslipidemia And Carotid Intima-Media Thickness In Children With Refractory Nephrotic Syndrome: A Randomized Controlled Trial. **Pediatric Nephrology**, vol 33, pp.2299-2309.
- Heller, F. R., Descamps, O. S., Hondekijna, J. C., Desager J. PP. 2000. **European Journal of Internal Medicine**, vol 11, pp.33-38.
- Huang, Y., & Mahley, R. 2014. Apolipoprotein E: Structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. **Neurobiology Of Disease**, vol 72, pp. 3-12.
- Johnson, R., Floege, J. and Feehally, J. 2019. Introduction to Glomerular Disease. **Comprehensive Clinical Nephrology** 6th Ed. New York: Hayle Medical.
- Kaneko, K., Tsuji, S., Kimata, T. et al. 2015. Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes. **World J Pediatr**, Vol. 11, pp.21–28. <https://doi.org/10.1007/s12519-015-0003-9>.
- Karam I., Yang Y. J and Li J. Y. 2017. Hyperlipidemia Background and Progress. **SM Atherosclerosis Journal**, vol 1 (1), pp. 1003.
- Kari, J. A., Tashkandi, M., Medhat, A. M., Khoja, S. O., Ramadan, K. S. 2012. Lipoprotein (a) and Other Dyslipidemia in Saudi Children with Nephrotic Syndrome (SSNS and SRNS). **Journal of Health Science**, vol 2, pp. 57-63.
- Katzung, B., Kruidering-Hall, M. and Trevor, A. 2019. **Katzung & Trevor's pharmacology**, 12th edition, New York: McGraw-Hill Education, pp. 359-361.

- Kaysen, G. & de Sain-van der Velden, M. 1999. New insights into lipid metabolism in the nephrotic syndrome. **Kidney International**, vol. 56, pp. S18-S21.
- Kluger, AY, Tecson, KM, Sudhakaran, S, Zhang, J et al. 2019. Statin Update: Intolerance, Benefit, and Beyond. **Hypertension Journal**. <https://doi.org/10.15713/ins.johtn.0141>
- Kocher, O. & Krieger, M. 2009. Role of the adaptor protein PDZK1 in controlling the HDL receptor SR-BI. **Current Opinion in Lipidology**, vol 20 (3), pp.236-241.
- Kocher, O., Yesilaltay, A., Shen, C., Zhang, S., Daniels, K., Pal, R., et al. 2008. Influence Of PDZK1 On Lipoprotein Metabolism And Atherosclerosis. **Biochimica et Biophysica Acta - Molecular Basis of Disease**, vol 1782, pp. 310-316.
- Kong, X., Yuan, H., Fan, J., Li, Z., Wu, T. and Jiang, L. 2013. Lipid-Lowering Agents For Nephrotic Syndrome. **Cochrane Database of Systematic Reviews**, vol 10 (12), pp. 1-38.
- Kusters, D. M., Caceres M, Coll M, et al. 2015. Efficacy and Safety of Ezetimibe Monotherapy in Children with Heterozygous Familial or Nonfamilial Hypercholesterolemia. **The Journal of Pediatrics**, vol 166 (6), pp. 1377–1378.
- Langslet, G., Breazna, A. and Drogari, E. 2016. a 3-year Study of Atorvastatin in Children and Adolescents with Heterozygous Familial Hypercholesterolemia. **Journal of Clinical Lipidology**, vol 10 (5), pp.1153-1162.
- Lim J, Lee J, Kim J, Hwang Y, Kim T, Lim S et al. 2017. Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. **International Journal of Chronic Obstructive Pulmonary Disease**, Vol. 12, pp.2465-2475. <https://doi.org/10.2147/COPD.S141295>
- Linton MRF, Yancey PG, Davies SS, et al. 2019. The Role of Lipids and Lipoproteins in Atherosclerosis. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK343489/>
- Liu, S. M & Vaziri, N. D., 2013. Role of PCSK9 and IDOL in the Pathogenesis of Acquired LDL Receptor Deficiency and Hypercholesterolemia in Nephrotic Syndrome. **Nephrology Dialysis Transplantation**, Volume 29 (3), pp. 538-543.
- McCrinkle, B. W., Ose, L, Marais, A. D. 2003. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. **The Journal of Pediatrics**; vol 143 (1), pp. 74–80.
- Miyashita Y, Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, and Watanabe H. 2002. Low Lipoprotein Lipase Mass in Preheparin Serum of Type 2 Diabetes Mellitus Patients and its Recovery with Insulin Therapy. **Diabetes Res Clin Pract**, 56, pp.181-187
- Moumita, G., Laskar, A. 2016. MYLIP/IDOL In Regulation To Cholesterol Metabolism. **Indian Journal of Ethnopharmacology**, vol 2 (1), pp.33-36
- Niaudet, PP., Matto, T. K., Kim, M. S. 2018. Etiology, Clinical Manifestations, and Diagnosis Of Nephrotic Syndrome In Children. UpToDate

- Noone, D., Iijima, K. and Parekh, R. 2018. Idiopathic Nephrotic Syndrome in Children. **The Lancet**, vol 392 (10141), pp.61-74.
- Nourbakhsh, N and Mak, R. 2017. Steroid-Resistant Nephrotic Syndrome: Past and Current Perspectives. **Pediatric Health, Medicine and Therapeutics**, vol 8, pp. 29-37.
- Nozue, T. 2017. Lipid Lowering Therapy and Circulating PCSK9 Concentration. **Journal of Atherosclerosis and Thrombosis**, vol 24, pp. 895-907.
- Oesterle, A., Laufs, U. and Liao, J. 2017. Pleiotropic Effects of Statins on the Cardiovascular System. **Circulation Research**, vol 120, pp. 229-243.
- O'Gorman C, S., O'Neill M, B., Conwell L, S. 2010. Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. **Vasc Health Risk Manag**, 20 (7), pp. 1-14.
- Olivecrona, G. 2016. Role of lipoprotein lipase in lipid metabolism. **Current Opinion in Lipidology**, vol 2, pp. 233-241.
- Paola M, Moreno R, Garcia P. 2011. Characteristics of idiopathic nephrotic syndrome at an unusual age in a tertiary-level pediatric hospital in Guadalajara, Jalisco, Mexico. **Bol Med Hosp Infant Mex**, Vol. 68, pp.250-256
- Pottel H, Hoste L, Delanaye P. 2014. Abnormal glomerular filtration rate in children, adolescents and young adults starts below 75 mL/min/1.73 m². **Pediatric Nephrology**, 30(5), pp.821-828. <https://doi.org/10.1007/s00467-014-3002-5>
- Pramana, PD., Mayetti, Kadri, H.. 2013. Hubungan antara Proteinuria dan Hipoalbuminemia pada Anak dengan Sindrom Nefrotik yang Dirawat di RSUP Dr. M. Djamil Padang periode 2009-2012. **Jurnal Kesehatan Andalas**, Vol. 2, pp.1-2.
- Querfeld U, Kohl B, Fiehn W, Minor T, Michalk D, Schaarer K, Muller-Wiefel DE. 1999. Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study. **Pediatric Nephrology**, vol 13 (1), pp. 7-12.
- Rader, D. J., Hobbs, H. H. 2015. **Harrison's Principles of Internal Medicine**, 19th edition, pp. 3215-3219.
- Radhakrishnan, J., Glassock, R. J., Rovin, B. H. & Lam, A. Q., 2018. Lipid Abnormalities in Nephrotic Syndrome. UptoDate.
- Rinsho, N. 2004. Refractory nephrotic syndrome. **PubMed**, vol 62 (10), pp. 1794-1799.
- Rosenson, R. S., Freeman, M. W., Saperia, G. M. 2018. Statins: Actions, Side Effects, and Administration. UptoDate.
- Sare Gülfem Özlü, Gülay Demircin, Nazan Tökmeci, Aysun Çaltık Yılmaz, Özlem Aydoğ, Mehmet Bülbül & Ayşe Öner. 2015. Long-term prognosis of idiopathic nephrotic syndrome in children, **Renal Failure**, 37:4, pp.672-677. <https://doi.org/10.3109/0886022X.2015.1010940>
- Sasaki M, Terao Y, Ayaori M, et al. 2014. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and lowdensity lipoprotein

- receptor-dependent pathways. **Arteriosclerosis Thrombosis and Vascular Biology**, vol 34 (6), pp. 1171–1178.
- Schachter, M. 2004. Chemical, pharmacokinetic and pharmacodynamics properties of statins: an update. **Fundamental & Clinical Pharmacology**, Vol. 19 (1), pp. 117-125.
- Schachter, M. 2004. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Blackwell Publishing **Fundamental & Clinical Pharmacology**, Vol. 19, pp.117-125.
- Schilling, J. A., Moreau, D., Robinson, J. M et al. 2005. **Pathophysiology a 2-in-1 Reference for Nurses**. Philadelphia: Lippincott Williams & Wilkins, pp. 544-546.
- Schneck, D. W., Birmingham, B. K., Zalikowski, J. A., et al. 2004. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. **Clinical Pharmacology & Therapeutics**, vol 75, pp. 455-463.
- Schwartz G, Work D. 2009. Measurement and Estimation of GFR in Children and Adolescents. **Clinical Journal of the American Society of Nephrology**, Vol. 4(11), pp.1832-1843. <https://doi.org/10.2215/CJN.01640309>.
- Siddall, E. & Radhakrishnan, J. 2012. The pathophysiology of edema formation in the nephrotic syndrome. **Kidney International**, vol 82, pp. 635-642.
- Sorrentino, V., Fouchier, S., Motazacker, M., Nelson, J., Defesche, J., Dallinga-Thie, G., Kastelein, J., Kees Hovingh, G. and Zelcer, N. 2013. Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoprotein. **European Heart Journal**, vol 34, pp. 1292-1297.
- Srinivasa, R.K., Prasad, T., Mohanta G.PP., Manna PP.K., 2011. An overview of statins as hypolipidemic drugs. **International Journal of Pharmaceutical Sciences and Drug Research**, vol. 3, pp.178-183.
- Stancu, C. and Sima, A. 2001. Statins: mechanism of action and effects. **Journal of Cellular and Molecular Medicine**, vol 5, pp. 378-387.
- Takahashi, S., Hiromura, K., Tsukida, M., Ohishi, Y., et al. 2013. Nephrotic Syndrome caused by Immune-Mediated Acquired LCAT Deficiency. **Journal of the American Society of Nephrology**, vol 24, pp. 1305-1312.
- Tapia C, Bashir K. 2019. Nephrotic Syndrome. StatPearls [Internet]. StatPearls Publishing. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470444/>
- Tkachenko, O. O., Scherier, R., Shchekochikhin, D. 2013. The Nephrotic Syndrome: Pathogenesis and Treatment of Edema Formation and Secondary Complications. **Pediatric Nephrology**, vol 29 (7), pp. 1159-1167.
- Vaziri, N. D. 2016. Disorders Of Lipid Metabolism In Nephrotic Syndrome: Mechanisms And Consequences. **Kidney International**, vol 90 (1), pp. 41-52.
- Vaziri, N. D., Liang, K. 2002. Upregulation of Acylcoenzyme A : Cholesterol Acyltransferase (ACAT) in Nephrotic Syndrome. **Kidney International**, vol. 61, pp. 1769–1775.

- Vidianty J, Pardede S, Hendarto A, Akib A. 2010. Obesity in Children with Frequent Relapse and Steroid Dependent Nephrotic Syndrome. **Paediatrica Indonesiana**, Vol. 50(3), pp.139. <https://doi.org/10.14238/pi50.3.2010.139-43>
- Viswanath, D. 2013. Nephrotic Syndrome in Children. **Journal of Indian Academy of Oral Medicine and Radiology**, vol 25 (1), pp.18-23.
- Wang, C. S., Hartsuck, J., & McConathy, W. J. 1992. Structure and Fuctional Properties of Lipoprotein Lipase. **Biochimica et Biophysica Acta-Lipids and Lipid metabolism**, vol 1123 (1), pp. 1-17.
- Wang, H., Garruti, G., Liu, M., Portincasa, PP. & Wang, D. 2017. Cholesterol and Lipoprotein Metabolism and Atherosclerosis: Recent Advances in Reverse Cholesterol Transport. **Annals of Hepatology**, vol 16, pp. S27-S42.
- Wang, X., Wang, L., Tu, Y., & Zhang, Y. 2018. Traditional Chinese Medicine for Refractory Nephrotic Syndrome: Strategies and Promising Treatments. **Evidence-Based Complementary and Alternative Medicine**, vol 2018, pp. 1-11.
- Weissel, RC. 2002. Body Mass Index as an Indicator of Obesity. *Asia Pacific J Clin Nutr*, Vol. 11, pp.S681–S684.
- Wirya WIGN. 2002. Sindrom Nefrotik. In: Alatas H, Tambunan T, Trihono PP, (penyunting). Buku ajar nefrologi anak jilid 2. Jakarta: Balai Penerbit FKUI, pp. 382-419.
- Yang J, Kim T, Koo B, Park B, Park J. 1999. Change of plasma lipoproteins by heparin-released lipoprotein lipase. **Experimental & Molecular Medicine**, 31(2), pp.60-64.
- Yoon, J. 2014. Dyslipidemia in Children and Adolescents: When and How to Diagnose and Treat?. **Pediatric Gastroenterology, Hepatology & Nutrition**, vol 17 (2), pp. 85-92.
- Zhang, C. P et al. 2015. IDOL, Inducible Degradar Of Low-Density Lipoprotein Receptor, Serves As A Potential Therapeutic Target For Dyslipidemia. **Medical Hypotheses**, vol 86, pp. 138-142
- Zhang, L., Reue, K., Fong, L., Young, S. and Tontonoz, PP. 2012. Feedback Regulation of Cholesterol Uptake by the LXR–IDOL–LDLR Axis. **Arteriosclerosis, Thrombosis, and Vascular Biology**, vol 32 (11), pp. 2541-2546.
- Zillerudo G, Sung, L., Freundlich, M., Strauss, J. 1984. Persistence of serum lipid abnormalities in chidlren with idiopathic nephrotic syndrome. **The Journal of Pediatrics**, vol 104 (1), pp. 61-65.